Post-earnings recap
Reported
Mon, Nov 10, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx's earnings report showed a larger-than-expected loss per share, which contributed to a significant drop in the stock price. Investors reacted negatively, likely due to the absence of revenue figures and guidance. The company's focus on clinical trials may indicate a longer-term strategy, but the immediate financial results raised concerns among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -10.38% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding upcoming projects. They emphasized their commitment to advancing their pipeline despite the current financial results.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.